

(Amount in '000)

	Note	As at 31st March, 2024	As at 31st March, 2023
EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	3	2,377.00	2,375.85
Reserves & Surplus	4	395,909.20	500,281.75
Money Received against Share Warrants	5	598.67	-
		398,884.87	502,657.60
Non-Current Liabilities			
Deferred Tax Liabilities (Net)	6	75.61	67.92
		75.61	67.92
Current Liabilities			
Trade Payables	7		
Due to micro and small enterprises		123.12	99.90
Due to others		24,703.26	6,518.54
Other Current Liabilities	8	6,569.29	2,743.11
Short-term Provisions	10	1,367.02	31.50
		32,762.69	9,393.05
TOTAL		431,723.16	512,118.55
ASSETS			
Non Current Assets			
Property, Plant & Equipment	9	1.39	4.22
Intangible Assets	9	516.16	554.39
		517.55	558.61
Non Current Investments	11	0.07	0.07
Long term Loans and Advances	12	13,414.77	12,194.95
Other non-current asstes	13	366,004.75	461,539.24
		379,419.59	473,734.26
Current Assets			
Cash and Cash Equivalents	14	7,870.38	6,570.48
Short-term Loans and Advances	15	1,432.92	621.55
Other Current Assets	16	42,482.73	30,633.64
		51,786.03	37,825.68
TOTAL		431,723.16	512,118.55

The accompanying notes forming part of the financial statements

In terms of our report attached

For, Dhirubhai Shah & Co LLP
Chartered Accountants
FRN: 102511W/W100298

For and on behalf of the board of directors

Anik S Shah
Partner
M.No: 140594

Jogin Desai
Director
DIN : 00067295

Rajani Battu
Director
DIN : 07253793

Place : Ahmedabad
Date : 06-09-2024

Place : Bangalore
Date : 06-09-2024

	Note	For the year ended 31st March, 2024	For the year ended 31st March, 2023
1 Revenue			
Revenue From Operation		-	-
2 Other Income	17	30,456.84	13,074.59
3 Total Income	(1 + 2)	30,456.84	13,074.59
4 Expenses			
Employee Benefits Expense	18	44,502.96	76,715.22
Depreciation and Amortisation Expense	9	41.06	41.06
Other Expenses	19	106,701.75	66,528.32
Total Expenses		151,245.78	143,284.60
5 Profit/(Loss) Before Tax	(3 - 4)	(120,788.94)	(130,210.01)
6 Tax Expense:			
Current Tax		-	-
Deferred Tax	6	7.70	13.68
Total tax expense		7.70	13.68
7 Profit/(Loss) After Tax	(5 - 6)	(120,796.64)	(130,223.69)
Earnings Per Share (EPS) (Face Value Rs. 10 Per Share)	29		
Basic EPS		(624.03)	(672.69)
Diluted EPS		(457.02)	(485.75)

See accompanying notes forming part of the financial statements

In terms of our report attached

For, Dhirubhai Shah & Co LLP
Chartered Accountants
FRN: 102511W/W100298

For and on behalf of the board of directors

Anik S Shah
Partner
M.No: 140594

Jogin Desai
Director
DIN : 00067295

Rajani Battu
Director
DIN : 07253793

Place : Ahmedabad
Date : 06-09-2024

Place : Bangalore
Date : 06-09-2024

Eyestem Research Private Limited
CIN : U74999KA2015PTC164505
Cash flow statement for the year ended 31st March, 2024

(Amount in '000)

	For the year ended 31st March, 2024	For the year ended 31st March, 2023
A: Cash flow from operating activities		
Net Profit/(loss) before tax	(120,788.94)	(130,210.01)
	<u>(120,788.94)</u>	<u>(130,210.01)</u>
Adjustments for :		
Depreciation and amortization	41.06	41.06
Employee Stock Options Outstanding	12,342.60	49,585.45
Unrealised Exchange loss/(gain) on foreign currency fluctuation	817.47	470.46
Interest income	(29,860.78)	(12,898.09)
	<u>(137,448.59)</u>	<u>(93,011.12)</u>
Operating cash flow before working capital changes		
Changes in working capital:		
Increase / (decrease) in trade payables	17,390.48	811.50
Increase / (decrease) in other current liabilities	5,161.70	952.21
Adjustments for increase/ (decrease) in operating assets:		
Decrease / (increase) in trade receivables	-	14.52
Decrease / (increase) in loans and advances	-	(1,778.33)
Decrease / (increase) in other current assets	(11,849.09)	(14,953.79)
Decrease / (increase) in other non-current assets	-	-
	<u>(126,745.51)</u>	<u>(107,965.01)</u>
Cash generated from operating activities		
Taxes paid	-	-
Net cash generated from operating activities (A)	<u>(126,745.51)</u>	<u>(107,965.01)</u>
B: Cash flow from investing activities		
Purchase of property, plant and equipment	-	-
Loans & Advances given	(2,031.19)	-
Investments in bank deposits	95,534.49	(460,815.55)
Interest received	29,860.78	12,621.41
	<u>123,364.09</u>	<u>(448,194.14)</u>
Net cash used in investing activities (B)		
C: Cash flow from financing activities		
Proceeds from equity shares issued	1,506.50	432,562.00
Grant received	2,576.14	-
Proceeds from long-term borrowings	598.67	-
Increase / (decrease) in other long-term Borrowings	-	-
	<u>4,681.31</u>	<u>432,562.00</u>
Net cash generated from financing activities (C)		
	<u>1,299.90</u>	<u>(123,597.15)</u>
Net (decrease)/increase in cash and cash equivalents (A+B+C)		
Cash and cash equivalents as at beginning of the year	6,570.48	130,167.63
Cash and cash equivalents as at end of the year/period	<u>7,870.38</u>	<u>6,570.48</u>

See accompanying notes forming part of the financial statements

Notes:

1. Cash and cash equivalents as at end of the year/period:

Cash on hand	13.46	12.52
With banks		
On current account	7,856.92	6,557.96
Balance In deposit accounts (Remaining maturity more than 3M to 12M)	-	-
Balance in deposit accounts (Remaining maturity of more than 12M)	-	-
Cash and cash equivalents (Refer Note No 13)	<u>7,870.38</u>	<u>6,570.48</u>

2. The Cash Flow Statement has been prepared under the 'Indirect Method' set out in AS - 3 "Cash Flow Statement"

3. Previous year figures have been re-grouped and re-cast wherever necessary to confirm to current year's classifications.

In terms of our report of even date

For, Dhirubhai Shah & Co LLP

Chartered Accountants

FRN: 102511W/W100298

For and on behalf of the board of directors

Anik S Shah

Partner

M.No: 140594

Jogin Desai

Director

DIN : 00067295

Rajani Battu

Director

DIN : 07253793

Place : Ahmedabad

Date : 06-09-2024

Place : Bangalore

Date : 06-09-2024

Eyestem Research Private Limited

CIN : U74999KA2015PTC164505

Notes to financial statements for the year ended 31st March 2024

1 Corporate information

The Company is a Private Limited Company, incorporated on 25th August, 2015 under the Companies Act, 2013. The Company primarily engaged in creating cell therapies for incurable diseases. The Company has started with the research work and has not received any operational income.

2 Significant accounting policies :

a. Basis of Preparation of Financial Statements

The Company is a Small and Medium Sized Company (SMC) as defined in the General Instructions in respect of Accounting Standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended). Accordingly, the Company has complied with the Accounting Standards as applicable to an SMC.

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards notified for SMC and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared on accrual basis under historical cost convention and on going concern basis.

b. Use of Estimates

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the period. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.

c. Tangible Assets

Fixed assets are stated at cost of acquisition including any attributable cost for bringing the assets to its working condition for its intended use, less accumulated depreciation and impairment losses, if any. Borrowing costs directly attributable to qualifying assets / capital projects are capitalized and included in the cost of fixed assets.

d. Intangible Assets

Patent cost is capitalised and recognised as Intangible Assets in terms of Accounting standard-26 "Intangible Assets" based on materiality, accounting prudence and significant economic benefits expected to flow therefrom for a period longer than one year.

e. Depreciation

i) Depreciation is provided on additions / deductions of the assets during the period from / upto the date in which the asset is added / deducted.

In respect of tangible assets, depreciation is provided based on useful life of the assets as prescribed in Schedule II to the Companies Act, 2013

In respect of intangible assets, cost of intangible assets are amortized over a period of its useful life.

ii) Depreciation on assets acquired / disposed off during the period is provided on pro-rata basis with reference to the date of addition/ disposal.

iii) Assets costing less than Rs. 5,000/- are written off in the period of purchase.

f. Revenue recognition

i) Interest income is accounted for on accrual basis.

g. Foreign exchange transactions

i) Transactions denominated in foreign currencies are normally recorded at the exchange rates prevailing at the time of the transaction.

ii) Non monetary foreign currency items are carried at cost.

iii) Exchange differences arising on settlement of monetary items or on reporting the company's monetary items at rates different from those at which they were initially recorded during the financial year are recognized as income or expense in the financial year in which they arise except for such adjustment of exchange difference arising on long term foreign currency monetary items in so far they related to the acquisition of a depreciable capital assets which are adjusted to the cost of the assets and depreciated over the remaining useful life of such assets.

h. Cash Flow Statement

The Cash Flow Statement is prepared in accordance with the format given under Accounting Standard-3 prescribed under rule 7 of the Companies (Accounts) rules, 2014 which separately identifies the cash flows from operating, investing and financing activities.

Eyestem Research Private Limited

CIN : U74999KA2015PTC164505

Notes to financial statements for the year ended 31st March 2024

i. Employee Stock Options

The Company determines the compensation cost based on the Black Scholes method. The compensation cost is amortized on a straight line basis over the vesting period.

j. Government Grants and Subsidies

Grants and subsidies from the government are recognised when there is reasonable assurance that

- (i) the Company will comply with the conditions attached to them, and
- (ii) the grant/subsidy will be received.

Government grants are treated as a part of the shareholders' funds and expense related to grant are adjusted against grant amount.

k. Earnings Per Share

Basic earnings per share is computed by dividing the profit/(loss) after tax by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit/(loss) after tax as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date.

l. Research Phase

The company understand that in the research phase of a project, it can not demonstrate that an intangible asset exists from which future economic benefits are probable. Therefore, the expenditure incurred in this phase is recognized as an expense when it is incurred.

m. Provisions, contingent liabilities and contingent assets

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

A possible obligation that arises from past events and the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the enterprise are disclosed as contingent liability and not provided for. Such liability is not disclosed if the possibility of outflow of resources is remote.

Contingent assets are neither recognized nor disclosed in the financial statements.

Eyestem Research Private Limited

CIN : U74999KA2015PTC164505

Notes to financial statements for the year ended 31st March 2024

(Amount in '000)

9 Property, Plant & Equipment & Intangibles

Particulars	Gross Block (at cost)				Depreciation and Amortization				Net Block	
	As At 1st April, 2023	Additions during the year	Deductions during the year	As at 31st March, 2024	As At 1st April, 2023	For the year	Deductions during the year	As at 31st March, 2024	As at 31st March, 2024	As at 31st March, 2023
Tangible assets										
Office Equipments	19.43		-	19.43	15.21	2.83	-	18.04	1.39	4.22
Total tangible assets	19.43	-	-	19.43	15.21	2.83	-	18.04	1.39	4.22
Intangible assets										
Patent	764.67		-	764.67	210.28	38.23	-	248.51	516.16	554.39
Total Intangible assets	764.67	-	-	764.67	210.28	38.23	-	248.51	516.16	554.39
Total fixed assets	784.10	-	-	784.10	266.55	41.06	-	266.55	517.55	558.61
Previous Year	775.62	8.49	-	784.11	184.43	41.06	-	184.43	599.68	
Total Block									517.55	

3 Equity Share Capital

Particulars	As at 31st March 2024	As at 31st March 2023
Authorised Share Capital 2,00,000 equity shares of Rs. 10 each (As at March-2023 - 2,00,000) Equity Shares	2,000.00	2,000.00
	<u>2,000.00</u>	<u>2,000.00</u>
Issued, Subscribed and fully paid-up equity shares with voting rights 1,93,680 (As at 31st March, 2023 - 1,93,565) fully paid up equity shares of Rs. 10 each	1,936.80	1,935.65
	<u>1,936.80</u>	<u>1,935.65</u>

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 31st March 2024		As at 31st March 2023	
	No. Shares	Amount	No. Shares	Amount
Equity Shares				
Opening Balance	193,565	1,935.65	193,565	1,935.65
Issued during the year (*)	115	1.15	-	-
Outstanding at the end of the period	<u>193,680</u>	<u>1,936.80</u>	<u>193,565</u>	<u>1,935.65</u>

(*)

During the year company has converted 115 share warrants in to 115 equity shares (face value of Rs. 10/- each) of Rs. 13,100/- (Including share premium of Rs. 13,090/- per share)

b. Terms/rights attached to equity shares

The Company has only one class of equity shares having par value of Rs. 10 per share. Each holder of equity shares is entitled to vote per share.

c. Details of shareholders holding more than 5% shares in the Company

Particulars	As at 31st March 2024		As at 31st March 2023	
	No. Shares	%	No. Shares	%
Mr. Jogin Desai	54,263	28.02%	54,263	28.03%
Ms. Rajani Battu	11,734	6.06%	12,497	6.46%
Escape Velocity Accelerator India Private Limited	14,500	7.49%	14,500	7.49%
Cytespace Research Private Limited	27,156	14.02%	33,492	17.30%
Jacesa Investment Limited	29,997	15.49%	26,829	13.86%
Innovative Quest LLP	9,886	5.10%	-	0.00%
	<u>147,536</u>	<u>76.18%</u>	<u>141,581</u>	<u>73.14%</u>

d. Shares held by Promoters at the end of the year 31st March, 2024

Name of Promotor	Class of Shares	No. of Shares	% of Total Shares	% Change during the year
Rajani Battu	Equity	11,734	6.06%	0.00%

d. Shares held by Promoters at the end of the year 31st March, 2023

Name of Promotor	Class of Shares	No. of Shares	% of Total Shares	% Change during the year
Rajani Battu	Equity	12,497	6.45%	0.00%

3.1 Preference Share Capital

Particulars	As at 31st March 2024	As at 31st March 2023
Authorised Share Capital 5,65,900 preference shares of Rs. 10 each (As at March-2023 -5,65,900) Preference Shares	5,659.00	5,659.00
38,800 preference shares (Series A) of Rs. 10 each (As at March-2023 -38,800) Preference Shares	388.00	388.00
	<u>6,047.00</u>	<u>6,047.00</u>
Issued, Subscribed and fully paid-up equity shares with voting rights 11,000 (As at 31st March, 2023- 11,000) fully paid up preference shares of Rs. 10 each	110.00	110.00
33,020 (As at 31st March, 2023 - NIL) fully paid up preference shares (Series A) of Rs. 10 each	330.20	330.20
	<u>440.20</u>	<u>440.20</u>

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 31st March 2024		As at 31st March 2023	
	No. Shares	Amount	No. Shares	Amount
Compulsorily Convertible Preference Shares				
Opening Balance	11,000	110.00	11,000	110.00
Issued during the year	-	-	-	-
Outstanding at the end of the period	11,000	110.00	11,000	110.00
Compulsorily Convertible Preference Shares (Series A)				
Opening Balance	33,020	330.20	33,020	330.20
Issued during the year	-	-	-	-
Outstanding at the end of the period	33,020	330.20	33,020	330.20

b. Terms/rights attached to Preference Shares

The Company shall, on or before the completion of 5 (five) years from the closing Date, convert the Subscription securities into equity shares of Rs. 10/- each the company

C. Details of shareholders holding more than 5% shares in the Company

Particulars	As at 31st March 2024		As at 31st March 2023	
	No. Shares	%	No. Shares	%
Kotak Investment Advisors Ltd.	6,863	15.59%	6,863	15.59%
Endiya Trustee Private Limited	9,863	22.41%	9,863	22.41%
Alkem Laboratories Limited	11,452	26.02%	11,452	26.02%
NATCO Pharma Limited	5,726	13.01%	5,726	13.01%
Fastspeed Vanijya LLP	2,863	6.50%	2,863	6.50%
Biological E Limited	5,725	13.01%	5,725	13.01%
	42,492	96.53%	42,492	96.53%

4 Reserves and Surplus

Particulars	As at 31st March 2024	As at 31st March 2023
a. Securities Premium		
Opening Balance	681,888.55	249,656.75
Addition during the year	1,505.35	432,231.80
Closing Balance	683,393.90	681,888.55
b. Surplus in the Statement of Profit and Loss		
Opening Balance	(257,941.00)	(127,717.31)
Profit/(Loss) for the period	(120,796.64)	(130,223.69)
Closing Balance	(378,737.64)	(257,941.00)
c. Grant Amount		
Opening Balance	148.32	148.32
Addition during the year	6,608.15	4,620.45
Less: Adjustment	(4,032.01)	(4,620.45)
Closing Balance	2,724.46	148.32
d. Employee Stock Options Outstanding (Refer Note 23)		
Opening Balance	76,185.88	26,600.43
Add: Transfer from P&L	12,342.60	49,585.45
	88,528.48	76,185.88
Closing Balance	395,909.20	500,281.75

5 Money Received against Share Warrants

Particulars	As at 31st March 2024	As at 31st March 2023
Money Received against Share Warrants (*)	598.67	-
	598.67	-

(*) During the year, the company has issued 573 Share warrants at the price of Rs. 1,310 per warrants. Out of this company has converted 115 warrants in to Equity Share Capital (inclusive of Rs. 13,090 as security premium and Rs. 10 as face value)

(Amount in '000)

6 Deferred Tax Liabilities Net

Particulars	As at 31st March 2024	As at 31st March 2023
Deferred Tax Liability		
Timing difference between book and tax depreciation	75.61	67.91
Net Deferred Tax Liability	75.61	67.91

7 Trade Payables

Particulars	As at 31st March 2024	As at 31st March 2023
Unsecured considered good:		
Due to Micro and small enterprises	123.12	99.90
Due to others	24,703.26	6,518.54
	24,826.38	6,618.44

7.1 Trade Payable ageing schedule as at 31 March 2024

Particulars	Outstanding for following periods from date of transaction				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	123.12	-	-	-	123.12
Others	24,703.26	-	-	-	24,703.26
Disputed dues- MSME	-	-	-	-	-
Disputed dues- Others	-	-	-	-	-
Total	24,826.38	-	-	-	24,826.38

7.2 Trade Payable ageing schedule as at 31 March 2023

Particulars	Outstanding for following periods from date of transaction				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	99.90	-	-	-	99.90
Others	6,415.02	103.52	-	0	6,518.54
Disputed dues- MSME	-	-	-	0	-
Disputed dues- Others	-	-	-	0	-
Total	6,514.92	103.52	-	-	6,618.44

8 Other Current Liabilities

Particulars	As at 31st March 2024	As at 31st March 2023
Statutory liabilities	4,389.95	1,913.98
Payable to Employees (*)	2,067.60	826.63
Credit Card Dues Payable	111.74	-
Refundable Share Application Money	-	2.50
	6,569.29	2,743.11

(*) Includes Payable to Directors

10 Short Term Provisions

Particulars	As at 31st March 2024	As at 31st March 2023
Provision for expenses	1,367.02	31.50
	1,367.02	31.50

11 Investments

Particulars	As at	As at
	31st March 2024	31st March 2023
Investment in subsidiary Company (100 Share of 0.01 USD each)	0.07	0.07
	0.07	0.07

Company has 100% stake in equity shares of Eyestem Research Inc, United States of America which is engaged in research business.

12 Long Term Loans & Advances

Particulars	As at	As at
	31st March 2024	31st March 2023
Unsecured, considered good		
Loan to wholly owned Subsidiary	13,414.77	12,194.95
	13,414.77	12,194.95

The loan to wholly owned subsidiary carries interest rate of 10% per annum.

13 Other non-current asstes

Particular	As at	As at
	31st March 2024	31st March 2023
Security Deposit	1,019.40	723.69
Balance in deposit accounts (Refer Note 13)	364,985.35	460,815.55
	366,004.75	461,539.24

14 Cash and Cash Equivalents

Particulars	As at	As at
	31st March 2024	31st March 2023
Balances with banks		
In Current Accounts	7,856.92	6,557.96
Cash on hand	13.46	12.52
Other Bank Balances		
Balance in deposit accounts (Remaining maturity of more than 12 months)	364,985.35	460,815.55
Less : Amount disclosed under other non-current assets (Refer Note 11)	(364,985.35)	(460,815.55)
	7,870.38	6,570.48

15 Short Term Loans & Advances

Particulars	As at	As at
	31st March 2024	31st March 2023
Advance to Suppliers	1,387.92	511.55
Advance to Employees	45.00	110.00
	1,432.92	621.55

(Amount in '000)

16 Other Current Assets

Particulars	As at 31st March 2024	As at 31st March 2023
Balances with government authorities	37,776.05	24,954.29
Prepaid expenses	62.95	68.66
Interest accrued on deposits	4,639.33	5,606.29
Other Receivables	4.40	4.40
	42,482.73	30,633.64

17 Other Income

Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
Interest Income	29,860.78	12,898.09
Interest on IT Refund	46.06	21.43
Handling Income	20.00	155.08
Research Income	10.00	-
Sponsorship Income	520.00	-
	30,456.84	13,074.59

18 Employee Benefit Exps

Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
Salaries, wages and allowances	28,195.21	26,541.50
Contribution to provident and other funds	655.20	504.00
Employees welfare expenses	175.77	84.27
Gratuity Expenses	3,134.18	-
Employees Compensation Expense (ESOP)	12,342.60	49,585.45
	44,502.96	76,715.22

19 Other Expenses

Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
Rent	-	20.00
Insurance	283.28	251.47
Advertisement & Marketing	107.82	45.22
Grant Expense	-	2,036.46
Legal and Professional	40,113.96	6,885.24
Research Expense (Refer Note 21)	58,401.31	52,444.28
Printing & Stationery	24.33	35.00
Statutory auditors remuneration (Refer Note 22)	35.00	38.00
Stamp Duty Expense	1.08	445.94
Bank Charges	184.21	53.32
Travelling & Conveyance	4,581.62	2,399.15
Seminar & Conference Expense	336.08	14.38
Foreign Exchange Fluctuation Loss	817.47	470.46
Miscellaneous expenses	28.20	86.51
Repair & Maintenance	10.50	-
Membership & Subscription	330.67	-
Office expenses	416.12	55.86
Communication expenses	1,030.09	1,247.05
	106,701.75	66,528.32

20 Contingent liabilities and Commitments, (to the extent, not provided for) - NIL.
Estimated amount of contract remaining to be executed on Capital Account - NIL

21 The Company is a Small and Medium Sized Company as defined in the General Instructions in respect of Accounting Standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended). Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company. Accordingly, the requirements of preparation and presentation of Segment Reporting (Accounting Standard - 17 "Segment Reporting") is not applicable.

22 Research Expense

Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
Research Consultancy	47,605.72	43,076.20
Laboratory Rent (Usage) Charges	6,413.26	4,929.51
Reagent Expense	4,382.33	4,438.57
	58,401.31	52,444.28

23 Payment to Auditors

Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
Statutory Audit fees	35.00	38.00
	35.00	38.00

24 Employee Stock Option Plan

The Company has established Employee Stock Option Plan (ESOP) for compensation to its employees. The Company had granted NIL options in current year (3468 options in the previous year) under the plan at an exercise price Rs. 10/- each fully paid. The exercised period shall continue as long as the grantee is an employee of the company.

The Compensation cost is computed under the fair value method and amortised in the year in which option granted were available for exercise.

For the Options granted the difference between the fair value of the Options in the year of grant and the options exercise price is charged to the statement of Profit & Loss.

Option activity under the plans is as given as below:

Particulars	2023-24	2022-23
Options granted, beginning of year (In numbers)	27,008	23,540
Granted during the year (In numbers)	-	3,468
Exercised during the year (In numbers)	Nil	Nil
Forfeited/Expired during the year (In numbers)	600	-
Options granted, end of the year (In numbers)	26,408	27,008
Option exercisable at the year end (In numbers)	-	-
Weighted average of remaining contractual life (years) at the year end	4	5

The fair value of the shares issued at the grant date was determined the Black Scholes Merton Method. The valuation of the shares were carried out in the month July 2022 and the Company has used the same fair value of Employee Stock Option Plan.

The Company has used the following assumption to arrive at the fair value based on Black Scholes Method. Risk free interest rate is considered at 7.39%, Adopted Beta is 1.25 and market Risk Premium is considered at 4.92%. The weighted average The risk free cost of capital arrived by the Company is 18.05%

25 Employee Benefit Plans

(A) Defined Benefit Plan

The Company has adopted Accounting Standard AS 15 (Revised 2005) – Employee Benefits.

The Company has entered into a defined contribution plan under the LIC Gratuity Scheme for its employees. This scheme is designed to provide gratuity benefits to employees upon their retirement or termination of employment, in accordance with applicable regulations and company policy.

Following data is provided relating to actuarial valuation of employee benefits received from LIC Gratuity Scheme:

Particulars	(Amount in 000)	
	For the year ended 31st March, 2024	For the year ended 31st March, 2023
The details of gratuity as required under AS-15 (revised):		
i. Reconciliation of Opening and Closing Balances of defined benefit obligation		
Liability at the beginning of the year	2,801.05	-
Current Service Cost	333.13	-
Benefits Paid	-	-
Interest Cost	-	-
Unrecognised Past Service Cost-non vested benefits	-	-
Benefit paid	-	-
Net Actuarial losses (gain) recognized	-	-
Liability at the end of the year	3,134.18	-
ii. Reconciliation of Opening and Closing Balances of Plan Assets		
Opening Fair value of Plan Assets	-	-
Transfer in/(out) obligations	-	-
Return on Plan Assets	-	-
Expected Return on Plan Assets	-	-
Contributions by Employer	3,134.18	-
Benefit paid	-	-
Net Actuarial losses (gain) recognized	-	-
Closing Fair Value of Plan Assets	3,134.18	-
iii. Reconciliation of the Present value of defined benefit obligation and Fair value of plan assets :		
Obligations at the end of the year	3,134.18	-
Plan assets at the end of the year, at Fair value	3,134.18	-
Asset / (Liability) recognized in balance sheet as at the end of the year	-	-
iv. Gratuity Cost for the year :		
Current service cost	333.13	-
Interest cost	-	-
Expected return on plan assets	-	-
Actuarial (Gain) or Loss	-	-
Past service cost- non vested benefit	2,801.05	-
Unrecognised Past Service Cost-non vested benefits	-	-
Net Gratuity cost	3,134.18	-
v. Actuarial Assumptions :		
Discount Rate (per annum)	7.25%	-
Annual Increase in Salary Cost	7%	-
Mortality	LIC(2006-08) ultimate	-
Retirement Age	60 Years	-
Actuarial Valuation Method	Project Unit Credit Method - AS 15	-

26 Related party disclosures as required by Accounting Standard – 18 issued by the Institute of Chartered Accountants of India:-

a. Names of related parties & description of relationship :

Nature of Relationship	Name of Related Parties
Key management personnel	Mr. Jogin Desai, Director Mr. Suresh Ramu, Director Mr. Ashok Nana Vohra, Director Mr. Ramaswamy Subramanian, Director Mr. Gerardus Adrianus Hoogland, Director Mr. Rajani Ravindra Battu, Director Mr. Dhruv Sareen, Director Mr. Mahendra Rao, Director
Enterprises controlled by Key Management Personnel	Cytespace Research Private Limited
Subsidiary	Eyestem Research Inc.

b. Transaction with related parties

Related Party	Nature of Transaction	For the year ended 31st March, 2024	For the year ended 31st March, 2023
Mr. Jogin Desai	Reimbursement of Expense	482.43	942.03
Mr. Jogin Desai	Managerial Remuneration	10,920.00	10,938.06
Mr. Rajani Battu	Managerial Remuneration	5,040.00	4,200.00
Mr. Rajani Battu	Reimbursement of Expense	146.56	118.62
Mr. Mahendra Rao	Reimbursement of Expense	146.59	1,514.24
Eyestem Research Inc.	Interest Income on loans	1,219.82	1,108.37

c. Balances with related parties

Related Party	Nature of Transaction	As at 31st March 2024	As at 31st March 2023
Mr. Jogin Desai	Outstanding Balance	679.16	84.24
Mr. Rajani Battu	Outstanding Balance	318.30	-
Eyestem Research Inc.	Loan to subsidiary	13,414.77	12,194.95

27 Earnings in Foreign Currencies

Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
Interest Income	1,219.82	1,108.37
	1,219.82	1,108.37

28 Expenditure made in Foreign Currencies

Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
Licence Fees	2,411	-
Professional and Consultation Fees	8,496.44	1,690.00
Seminar Expense	-	14.38
Research Expense	2,915.55	-
Travel Expense	559.61	45.16
Contract Service	28,789.25	37,009.93
	43,171.54	38,759.47

29 Pursuant to the Accounting Standard (AS- 20) – Earnings per Share, the disclosure is as under:

Particulars	As at	
	31st March 2024	31st March 2023
Basic and Diluted EPS		
Net Profit/(Loss) after tax as per Statement of Profit and Loss attributable to shareholders	(120,797)	(130,210)
Weighted average number of equity shares outstanding during the period	Nos. 193,576	193,565
Weighted average number of preference shares outstanding during the period	Nos. 44,020	44,020
Weighted average number of share Warrants outstanding during the period	Nos. 311	-
Weighted average number of ESOP outstanding during the period	Nos. 26,408	30,476
Nominal Value of equity share	Rs. 10	10
Basic Earnings Per Share	(624.03)	(672.69)
Diluted Earnings Per Share	(457.02)	(485.75)

30 Additional Discloser As Per New Schedule iii Requirements :

- A. The Company has not carried out any revaluation of Property, Plant and Equipment in any of the period reported in this Financial Statements hence reporting is Not Applicable.
- B. There have been no proceedings initiated or pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.
- C. There are no borrowings in a Company and so security of current assets against borrowings is not applicable
- D. As per the internal assessment of the Management, the Company does not have any transactions with companies struck off.
- E. There no charges or satisfaction of charges yet to be registered with Registrar of Companies beyond the statutory period.
- F. There are no undisclosed income surrendered or disclosed as income during the period / year in the tax assessment under the Income Tax Act, 1961.
- G. The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (intermediaries) with the understanding tht the intermediary Shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- (b) provide any gurantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- H. The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recored in writing or otherwise) that the Company shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- (b) provide any gurantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- I. The Company is not declared as willful defaluter by any bank or Financial Institution as on the Balance Sheet.
- J. During the year, the Company has not traded or invested in Crypto Currency or Virtual Currency.

31 Key Ratios

Particulars	Numerator	Denominator	31 March 2024	31-Mar-2023	Remarks for variance more than 25%
(a) Current Ratio (in times)	Current Assets	Current Liabilities	1.58	4.03	Due to decreased in current liabilities
(b) Debt-Equity Ratio (in times)	Total Debt (Non-current borrowings + Current Borrowings)	Equity	-	-	
(c) Debt Service Coverage Ratio (in times)	Net profit after taxes + Exception items + Noncash operating expenses (depreciation) +	Interest payments+ Long-term Principal Repayment	-	-	
(d) Return on Equity Ratio (in %)	Net Profit after taxes	Average Shareholder's Equity	-30.28%	-25.91%	Due to Loss increased compared to previous year
(e) Trade Receivables turnover ratio (in times)	Revenue from Operations (Net)	Average Trade Receivables	-	-	
(f) Trade payables turnover ratio (in times)	Total Purchases	Average Trade Payables	-	-	
(g) Net capital turnover ratio (in times)	Revenue from Operations (Net)	Working Capital	-	-	
(h) Net profit ratio (in %)	Net Profit after taxes	Revenue from Operations (Net)	-	-	
(i) Return on Capital employed (in %)	EBIT	Capital employed (Tangible Networth + Total Debt)	-30.27%	-15.24%	Due to higher operating expenses ratio has been decreased
(j) Return on Investment(in %)	EBIT	Total Assets	-27.97%	-25.43%	Due to higher operating expenses ratio has been decreased

32 Previous year's figures have been regrouped wherever necessary.

Signature to Notes 1 to 32

In terms of our report attached

For, Dhirubhai Shah & Co LLP
Chartered Accountants
FRN: 102511W/W100298

For and on behalf of the board of directors

Anik S Shah
Partner
M.No: 140594

Jogin Desai
Director
DIN : 00067295

Rajani Battu
Director
DIN : 07253793

Place : Ahmedabad
Date : 06-09-2024

Place : Bangalore
Date : 06-09-2024